Suppression of Myoclonus in Corticobasal Degeneration by Levetiracetam
Jae Wook Cho, Jae Hyeok Lee
JMD. 2014;7(1):28-30.   Published online 2014 Apr 30     DOI: https://doi.org/10.14802/jmd.14007
Citations to this article as recorded by Crossref logo
Chinese nutraceuticals and physical activity; their role in neurodegenerative tauopathies
Abdullahi Alausa, Sunday Ogundepo, Barakat Olaleke, Rofiat Adeyemi, Mercy Olatinwo, Aminat Ismail
Chinese Medicine.2021;[Epub]     CrossRef
Four-Repeat Tauopathies: Current Management and Future Treatments
Lawren VandeVrede, Peter A. Ljubenkov, Julio C. Rojas, Ariane E. Welch, Adam L. Boxer
Neurotherapeutics.2020; 17(4): 1563.     CrossRef
Physiology-Based Treatment of Myoclonus
Ashley B. Pena, John N. Caviness
Neurotherapeutics.2020; 17(4): 1665.     CrossRef
Available and future treatments for atypical parkinsonism. A systematic review
Davide Vito Moretti
CNS Neuroscience & Therapeutics.2019; 25(2): 159.     CrossRef
An Update on Myoclonus Management
Christine M. Stahl, Steven J. Frucht
Expert Review of Neurotherapeutics.2019; 19(4): 325.     CrossRef
Corticobasal degeneration: key emerging issues
F. Ali, K. A. Josephs
Journal of Neurology.2018; 265(2): 439.     CrossRef
Focal Predominant Forms of Posthypoxic Action Myoclonus
Carmen Gasca-Salas, Anthony E. Lang
Movement Disorders Clinical Practice.2016; 3(4): 417.     CrossRef
Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options
Ruth Lamb, Jonathan D. Rohrer, Andrew J. Lees, Huw R. Morris
Current Treatment Options in Neurology.2016;[Epub]     CrossRef
An Update and Review of the Treatment of Myoclonus
Kelly Mills, Zoltan Mari
Current Neurology and Neuroscience Reports.2015;[Epub]     CrossRef